NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Forecast, Price & News

$5.88

+0.61 (+11.57%)

(As of 06/1/2023 ET)

Compare

Today's Range: $5.25
▼
$5.88
50-Day Range: $2.14
▼
$5.88
52-Week Range: $0.85
▼
$5.88

Volume: 131,715 shs
Average Volume: 188,486 shs
Market Capitalization: $48.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Soleno Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 36.1% Upside
$8.00 Price Target
Short Interest: Healthy
1.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 1.19
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$647,150 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.71) to ($0.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

305th out of 1,980 stocks

Electromedical Equipment Industry

5th out of 46 stocks

3.5

Analyst's Opinion

Consensus Rating
Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Soleno Therapeutics has a forecasted upside of 36.1% from its current price of $5.88.
Amount of Analyst Coverage
Soleno Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.25% of the float of Soleno Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Soleno Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Soleno Therapeutics has recently increased by 14.70%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Soleno Therapeutics does not currently pay a dividend.
Dividend Growth
Soleno Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Soleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Soleno Therapeutics is -0.55.

2.9

News and Social Media Coverage

News Sentiment
Soleno Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Soleno Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soleno Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $647,150.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
23.70% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($1.71) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Soleno Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Soleno Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Soleno Therapeutics has a P/B Ratio of 18.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Soleno Therapeutics (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

May 31, 2023 | americanbankingnews.com

Analyzing Soleno Therapeutics (NASDAQ:SLNO) and Nexalin Technology (NASDAQ:NXL)

May 28, 2023 | americanbankingnews.com

Perceptive Advisors Llc Buys 22,500 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock

June 2, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.

May 28, 2023 | americanbankingnews.com

Perceptive Advisors Llc Acquires 25,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock

May 25, 2023 | msn.com

Oppenheimer Reiterates Soleno Therapeutics (SLNO) Outperform Recommendation

May 25, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Soleno Therapeutics (SLNO) and Bioline RX Ltd Sponsored ADR (BLRX)

May 25, 2023 | americanbankingnews.com

Perceptive Advisors Llc Purchases 27,300 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock

May 24, 2023 | americanbankingnews.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Perceptive Advisors Llc Buys 25,200 Shares

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 8, 2023 | americanbankingnews.com

Soleno Therapeutics (NASDAQ:SLNO) versus Movano (NASDAQ:MOVE) Critical Contrast

May 3, 2023 | finance.yahoo.com

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

April 26, 2023 | finance.yahoo.com

Here's Why We're A Bit Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

March 28, 2023 | finance.yahoo.com

Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

March 28, 2023 | americanbankingnews.com

Oppenheimer Comments on Soleno Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:SLNO)

March 27, 2023 | americanbankingnews.com

Oppenheimer Reaffirms Outperform Rating for Soleno Therapeutics (NASDAQ:SLNO)

March 21, 2023 | finance.yahoo.com

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

March 18, 2023 | seekingalpha.com

SLNO Soleno Therapeutics, Inc.

March 16, 2023 | finance.yahoo.com

Soleno Therapeutics, Inc.'s (NASDAQ:SLNO) Shift From Loss To Profit

March 7, 2023 | finance.yahoo.com

Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

February 9, 2023 | finance.yahoo.com

7 Top Short-Squeeze Candidates to Watch in February

January 30, 2023 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

January 29, 2023 | reuters.com

SLNO.OQ - | Stock Price & Latest News | Reuters

January 26, 2023 | finance.yahoo.com

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

December 20, 2022 | msn.com

Peering Into Soleno Therapeutics's Recent Short Interest

December 19, 2022 | marketwatch.com

Soleno Therapeutics Shares Double After Financing Commitment

December 19, 2022 | markets.businessinsider.com

Why Is Soleno Therapeutics (SLNO) Stock Up 130% Today?

December 19, 2022 | marketwatch.com

Thinking about buying stock in Mullen Automotive, Soleno Therapeutics, Agrify, AMC Entertainment, or Amyris?

See More Headlines

SLNO Price History

30 days | 90 days | 365 days | Advanced Chart

SLNO Company Calendar

Last Earnings: 3/21/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SLNO
CUSIP: N/A
CIK: 1484565
Web: www.soleno.life
Phone: (650) 213-8444
Fax: 650-213-8383
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +36.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.1196)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -220.22%
Return on Assets: -92.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.18
Quick Ratio: 1.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.32 per share
Price / Book: 18.38

Miscellaneous

Outstanding Shares: 8,170,000
Free Float: 6,233,000
Market Cap: $48.04 million
Optionable: Not Optionable
Beta: 0.22

Key Executives

Anish Bhatnagar
President, Chief Executive & Operating Officer

James H. Mackaness
Chief Financial Officer

Kristen Yen
Vice President-Clinical Operations

Michael Woloschak
Vice President-Clinical Development

Harish Ravivarapu
Vice President-Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SLNO Stock - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings or view top-rated stocks.
What is Soleno Therapeutics' stock price forecast for 2023?: 1 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' shares. Their SLNO share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts.
How have SLNO shares performed in 2023?: Soleno Therapeutics' stock was trading at $1.98 on January 1st, 2023. Since then, SLNO shares have increased by 197.0% and is now trading at $5.88.
View the best growth stocks for 2023 here.
When is Soleno Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SLNO earnings forecast.
How were Soleno Therapeutics' earnings last quarter?: Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Tuesday, March, 21st. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.18.
When did Soleno Therapeutics' stock split?: Soleno Therapeutics's stock reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).
What is Soleno Therapeutics' stock symbol?: Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
Who are Soleno Therapeutics' major shareholders?: Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Carlyle Group Inc. (14.71%), Renaissance Technologies LLC (0.94%), JPMorgan Chase & Co. (0.86%) and Dimensional Fund Advisors LP (0.37%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Perceptive Advisors Llc and William G Harris.
View institutional ownership trends.
How do I buy shares of Soleno Therapeutics?: Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Soleno Therapeutics' stock price today?: One share of SLNO stock can currently be purchased for approximately $5.88.
How much money does Soleno Therapeutics make?: Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $48.04 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.1196) on an earnings per share basis.
How can I contact Soleno Therapeutics?: Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.

This page (NASDAQ:SLNO) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial